Treatment of Idiopathic Multicentric Castleman's Disease With Sequential Thalidomide-Cyclophosphamide-Prednisone After Siltuximab:Report of One Case.
10.3881/j.issn.1000-503X.16284
- Author:
Yue DANG
1
;
Jian LI
1
;
Ya-Ping LUO
2
;
Lu ZHANG
1
Author Information
1. Department of Hematology, PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
2. Department of Nuclear Medicine,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Case Reports
- Keywords:
Castleman’s disease;
siltuximab;
thalidomide,cyclophosphamide,and prednisone regimen
- MeSH:
Humans;
Castleman Disease/drug therapy*;
Female;
Middle Aged;
Thalidomide/therapeutic use*;
Prednisone/therapeutic use*;
Cyclophosphamide/therapeutic use*;
Antibodies, Monoclonal/administration & dosage*
- From:
Acta Academiae Medicinae Sinicae
2025;47(3):483-486
- CountryChina
- Language:English
-
Abstract:
Castleman's disease is a rare polyclonal lymphoproliferative disorder.This article reports the diagnosis and treatment of a 45-year-old female patient with idiopathic multicentric Castleman's disease.The patient presented recurrent fever,enlarged lymph nodes,and elevated levels of inflammation markers.After multiple serological examinations and tissue biopsies,she was diagnosed with hyaline vascular-type Castleman's disease.Initially,the patient received siltuximab targeting interleukin-6,which significantly improved her condition.Considering the cost and convenience of long-term treatment,she subsequently switched the therapy to an oral treatment regimen of thalidomide,cyclophosphamide,and prednisone (TCP),which maintained disease control.This report aims to highlight the diagnostic complexity and diversity of treatment options for idiopathic multicentric Castleman's disease,demonstrating the potential of the TCP regimen as a cost-effective treatment choice.
